LL-37
Research OnlyAlso known as: Cathelicidin, hCAP18, Human Cationic Antimicrobial Peptide 18, CAMP, FALL-39, CAP18
The only human cathelicidin antimicrobial peptide, discovered at Karolinska Institute in Sweden (1995). A 37-amino acid peptide with broad-spectrum antimicrobial activity and immunomodulatory functions. Extensive mechanistic research supports roles in innate immunity, wound healing, and host defense.
Research Statistics
Human cathelicidin with growing international research interest; membrane-disruption and immunomodulatory mechanisms are supported, but clinical trials are early-stage with limited human data.
Research Dossier
Overview
What is LL-37 and what does the research say?
Mechanism of Action
LL-37 is an endogenous human antimicrobial peptide with well-characterized mechanisms supported by extensive research from laboratories worldwide, including foundational work from Karolinska Institute in Sweden.
How It Works (Simplified)
LL-37 functions as a multifunctional defense molecule through several parallel pathways:
Cationic (+6 charge) structure attracts to bacterial membranes, forming pores that cause cell lysis. Human cells are spared due to neutral membrane composition.
Binds bacterial LPS (endotoxin) with high affinity, preventing sepsis-inducing inflammatory cascades and protecting against toxic shock.
Activates FPRL1/FPR2 receptors to recruit neutrophils, monocytes, and T cells to infection sites, amplifying the immune response.
Promotes angiogenesis and keratinocyte migration via EGFR transactivation, accelerating tissue repair while providing antimicrobial protection.
Scientific Pathways
Membrane Disruption Pathway (Direct Antimicrobial)
LL-37 (+6 cationic charge) → Electrostatic attraction to anionic bacterial membrane
↓
Alpha-helix formation → Membrane insertion → Pore formation
↓
Cell lysis and deathFPRL1/FPR2 Signaling Pathway (Immunomodulation & Wound Healing)
LL-37 → FPRL1/FPR2 receptor → G-protein activation → Multiple effects:
├── Chemotaxis (immune cell recruitment)
├── EGFR transactivation → Keratinocyte migration
├── VEGF pathway → Angiogenesis
└── Cytokine modulationVitamin D Regulation Pathway (Endogenous Production)
Vitamin D → 1,25(OH)2D3 → VDR activation → CAMP gene transcription → hCAP18 → Proteinase 3 cleavage → Active LL-37Key Research: Liu PT et al. (2006) demonstrated vitamin D-induced LL-37 is essential for macrophage killing of M. tuberculosis. PMID:16497887
Important Limitations
- LL-37 activity is reduced at high salt concentrations
- Serum proteases rapidly degrade the peptide (short half-life)
- Excessive LL-37 or abnormal processing linked to psoriasis and rosacea
- Systemic delivery remains challenging; most applications are topical
- Production costs limit widespread therapeutic development
Evidence-Chained Benefits
Evidence-Chained Benefits
Research findings linked to mechanisms and clinical outcomes
What to Expect
Timeline based on observations from published studies. Individual responses may vary.
LL-37 exerts rapid antimicrobial effects upon contact with pathogens. Membrane disruption and bacterial killing occurs within minutes of exposure at sufficient concentrations.
Immunomodulatory effects begin including immune cell chemotaxis, cytokine modulation, and initiation of wound healing cascades via FPRL1/EGFR signaling.
Wound healing effects become apparent with increased keratinocyte migration, angiogenesis, and re-epithelialization. Clinical trials showed improved healing endpoints over 2-4 weeks.
Endogenous LL-37 production can be enhanced long-term through vitamin D optimization. Sustained vitamin D levels maintain elevated cathelicidin expression.
Research-Based Observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Quality Checklist
Visual indicators to help evaluate LL-37 product quality
Good Signs (6 indicators)
Warning Signs (5 indicators)
Bad Signs (6 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Peptide Interactions
Known and theoretical interactions when combining LL-37 with other peptides. Based on published research and mechanistic considerations.
BPC-157
SynergisticLL-37's antimicrobial and wound healing properties complement BPC-157's tissue repair mechanisms. May enhance wound healing outcomes through infection control plus regeneration.
Thymosin-Alpha-1
SynergisticBoth enhance innate immunity - LL-37 provides direct antimicrobial peptide activity while Ta1 modulates T-cell and dendritic cell responses. Complementary immune enhancement.
TB-500
CompatibleBoth promote wound healing - LL-37 via antimicrobial defense and angiogenesis, TB-500 via actin regulation and cell migration. Complementary mechanisms.
GHK-Cu
CompatibleLL-37's antimicrobial effects may protect healing tissue while GHK-Cu promotes collagen synthesis. Complementary wound healing pathways.
Selank
CompatibleSelank retains immunomodulatory activity from tuftsin backbone. Different immune modulation mechanisms with no known contraindications.
Semax
CompatibleBoth have immunomodulatory components - LL-37 as antimicrobial peptide, Semax via anti-inflammatory mechanisms. Different primary targets.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
References
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
Methodology Note
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare LL-37
LL-37 Calculators
Related Peptides
Alpha-Defensins
HNP-1, HNP-2, HNP-3 +5 more
A family of small cationic antimicrobial peptides (29-35 amino acids) that are key components of innate immunity in humans. Produced primarily by neutrophils (HNP-1 to 4) and Paneth cells (HD-5, HD-6), they exhibit broad-spectrum antimicrobial activity and immunomodulatory functions. Well-characterized biochemically with extensive research, though therapeutic development faces challenges.
KPV
Lys-Pro-Val, Lysine-Proline-Valine, alpha-MSH(11-13) +1 more
A naturally occurring tripeptide derived from the C-terminus of alpha-melanocyte-stimulating hormone (alpha-MSH). Preclinical studies demonstrate potent anti-inflammatory effects via NF-kB inhibition, but no human clinical trials have been conducted. Research has focused on inflammatory bowel disease and skin inflammation models.
Kristagen
EDG, Glu-Asp-Gly, Immune tripeptide
A synthetic tripeptide (Glu-Asp-Gly) developed by Russian scientist Vladimir Khavinson, claimed to regulate thymus function and support immune cell differentiation. No Western clinical validation exists; research is limited to Russian preclinical studies.
Lactoferricin
LFcinB, Lactoferricin B, LfcinB +1 more
An antimicrobial peptide derived from lactoferrin, a protein found in milk and other secretions. Shows broad-spectrum antimicrobial activity in laboratory studies. Research focuses on potential applications in infectious disease, food safety, and cancer. Primarily studied preclinically with very limited human clinical data. Not approved as a therapeutic by any regulatory agency.
Murepavadin
POL7080, RG7929
A first-in-class cyclic antimicrobial peptide targeting the LptD outer membrane protein of Pseudomonas aeruginosa. The first OMPTA (outer membrane protein targeting antibiotic) to reach clinical development. IV formulation discontinued due to nephrotoxicity; inhaled formulation continues Phase 3 development for cystic fibrosis and bronchiectasis patients.
Thymalin
Thymulin, Thymic Factor, Timalin +1 more
A thymic peptide complex developed in Russia and used clinically in the former Soviet Union for immunomodulation. Derived from calf thymus extract, it contains multiple peptides claimed to restore immune function. Approved in Russia since the 1970s but not recognized by Western regulatory agencies. Evidence comes primarily from Russian studies with limited Western replication.